Table 2.

Other factors and their association with overall survival.

	Patients (%)	HR (95% CI)	p Value
Body mass index (BMI)
Underweight	13 (5.1)	1.58 (0.55–4.51)	0.39
Normal weight	121 (47.1)	1.00
Overweight	84 (32.7)	0.85 (0.46–1.57)	0.60
Obese	39 (15.2)	0.89 (0.40–1.95)	0.76
Smoking status
Non-smoker	41 (16.0)	1.00
Ex-smoker	152 (59.1)	1.27 (0.56–2.88)	0.57
Current smoker	63 (24.5)	1.89 (0.79–4.53)	0.15
Symptoms
No	193 (75.1)	1.00
Yes	62 (24.1)	1.78 (1.03–3.07)	0.04
FEV1 %predicted
≥80	172 (66.9)	1.00
<80	84 (32.7)	1.67 (0.98–2.85)	0.06
FEV1/FVC (Tiffeneau)
≥70	147 (57.2)	1.00
<70	98 (38.1)	1.24 (0.72–2.12)	0.44
DLCO
≥70	72 (28.0)	1.00
<70	86 (33.5)	1.86 (0.98–3.52)	0.06
Histology
ADK	188 (73.2)	1.00
Epidermoid	54 (21.0)	2.25 (1.26–4.02)	0.006
Other NSCLC *	15 (5.8)	3.71 (1.63–8.44)	0.002
Stage
I	145 (56.4)	1.00
II	57 (22.2)	2.50 (1.28–4.91)	0.008
III	55 (21.4)	4.25 (2.27–7.95)	<0.0001
pN
pN0	187 (72.8)	1.00
pN1	33 (12.8)	2.41 (1.18–4.96)	0.02
pN2	33 (12.8)	4.17 (2.26–7.70)	<0.0001
Pleural invasion
Pl0	164 (63.8)	1.00
Pl+	93 (36.2)	2.78 (1.63–4.72)	0.0002
Perineural/vascular emboli
No	102 (39.7)	1.00
Yes	154 (59.9)	2.76 (1.62–4.73)	0.0002

FEV1: Forced-expiratory volume in 1 s; FEV1/FVC: Tiffeneau–Pinelli index; DLCO: diffusion capacity. Data are missing for the following variables: smoking (n = 1); symptoms (n = 2); FEV1 (n = 1); FEV1/FVC (n = 12); DLCO (n = 99); pN (n = 4); perineural invasion (n = 1). * 15 NSCLC (7 adeno-squamous, 4 sarcomatoid carcinomas, 4 undifferentiated carcinomas).